Tibet Cheezheng Tibetan Medicine Co., Ltd. (SHE:002287)
China
· Delayed Price · Currency is CNY 22.81
+0.19 (0.84%)
Apr 29, 2026, 1:55 PM CST
SHE:002287 Revenue
Tibet Cheezheng Tibetan Medicine had revenue of 405.25M CNY in the quarter ending March 31, 2026, with 0.56% growth. This brings the company's revenue in the last twelve months to 2.42B, up 1.78% year-over-year. In the year 2025, Tibet Cheezheng Tibetan Medicine had annual revenue of 2.42B with 3.34% growth.
Revenue (ttm)
2.42B
Revenue Growth
+1.78%
P/S Ratio
5.33
Revenue / Employee
762.85K
Employees
3,170
Market Cap
12.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.42B | 78.04M | 3.34% |
| Dec 31, 2024 | 2.34B | 292.82M | 14.32% |
| Dec 31, 2023 | 2.05B | 363.07K | 0.02% |
| Jan 1, 2023 | 2.04B | 274.30M | 15.49% |
| Jan 1, 2022 | 1.77B | 285.43M | 19.22% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Jan 1, 2019 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| InventisBio | 37.29M |
| Staidson (Beijing) BioPharmaceuticals | 203.92M |
| Inner Mongolia Furui Medical Science | 1.60B |
| Vcanbio Cell & Gene Engineering Corp., | 1.42B |
| Pacific Shuanglin Bio-pharmacy | 2.38B |
| Hualan Biological Vaccine | 1.20B |
| Chengdu Olymvax Biopharmaceuticals | 704.16M |
| Chongqing Genrix Biopharmaceutical | 230.72M |